MB-101 (Mustang Bio)

N/A

Report date: 2025/07/15 11:53:08

Base Information

Drug NameMB-101 (Mustang Bio)
Drug Alias NameAutologous IL13(EQ)BBzeta/CD19t+ TCM-enriched T Cells (Mustang Bio)IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes (Mustang Bio)MB-101
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-IL13RA2T lymphocyte replacements
TargetsInterleukin-13 receptor subunit alpha-2
Therapy Area/IndicationsCNS Embryonal TumorBrain NeoplasmsGlioblastoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMustang Bio IncCity Of Hope National Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesMustang Bio IncCity Of Hope National Medical Center
Inactive CompaniesN/A
Active IndicationsBrain NeoplasmsGlioblastomaGlioma
Inactive IndicationsCNS Embryonal Tumor

Other Information

ATC CodeN/A
Related LinksN/A